BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 36884274)

  • 21. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-Related Quality of Life among Women Breast Cancer Patients in Eastern China.
    Chen Q; Li S; Wang M; Liu L; Chen G
    Biomed Res Int; 2018; 2018():1452635. PubMed ID: 30065931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.
    Davie A; Carter GC; Rider A; Pike J; Lewis K; Bailey A; Price GL; Ringeisen F; Pivot X
    BMC Cancer; 2020 Sep; 20(1):855. PubMed ID: 32894087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
    King MT; Stockler MR; O'Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML;
    Qual Life Res; 2018 Jan; 27(1):59-74. PubMed ID: 29248998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial.
    Hassett MJ; Wong S; Osarogiagbon RU; Bian J; Dizon DS; Jenkins HH; Uno H; Cronin C; Schrag D;
    Trials; 2022 Jun; 23(1):506. PubMed ID: 35710449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
    Catto JWF; Downing A; Mason S; Wright P; Absolom K; Bottomley S; Hounsome L; Hussain S; Varughese M; Raw C; Kelly P; Glaser AW
    Eur Urol; 2021 May; 79(5):621-632. PubMed ID: 33581875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.
    Taarnhøj GA; Johansen C; Lindberg H; Basch E; Dueck A; Pappot H
    Cancer Med; 2020 May; 9(9):3078-3087. PubMed ID: 32154663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial.
    Meixner E; Wark A; Forster T; Weykamp F; Lang K; König L; Lindel K; Oelmann-Avendano JT; Krisam J; Schneeweiss A; Ellerbrock M; Mielke T; Hörner-Rieber J; Herfarth K; Debus J; Arians N
    Radiat Oncol; 2023 Jan; 18(1):5. PubMed ID: 36624483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.
    Gough N; Koffman J; Ross JR; Riley J; Judson I
    PLoS One; 2019; 14(9):e0210731. PubMed ID: 31557183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multilevel Characteristics of Cumulative Symptom Burden in Young Survivors of Childhood Cancer.
    Horan MR; Srivastava DK; Choi J; Krull KR; Armstrong GT; Ness KK; Hudson MM; Baker JN; Huang IC
    JAMA Netw Open; 2024 May; 7(5):e2410145. PubMed ID: 38713463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure.
    Feldman E; Pos FJ; Smeenk RJ; van der Poel H; van Leeuwen P; de Feijter JM; Hulshof M; Budiharto T; Hermens R; de Ligt KM; Walraven I
    ESMO Open; 2023 Feb; 8(1):100775. PubMed ID: 36652781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
    Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
    J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.
    Husson O; de Rooij BH; Kieffer J; Oerlemans S; Mols F; Aaronson NK; van der Graaf WTA; van de Poll-Franse LV
    Oncologist; 2020 Apr; 25(4):e722-e732. PubMed ID: 32297435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events.
    Yang SS; Chen L; Liu Y; Lu HJ; Huang BJ; Lin AH; Sun Y; Ma J; Xie FY; Mao YP
    BMC Cancer; 2021 Jul; 21(1):860. PubMed ID: 34315423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
    King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
    Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.
    Basch E; Schrag D; Henson S; Jansen J; Ginos B; Stover AM; Carr P; Spears PA; Jonsson M; Deal AM; Bennett AV; Thanarajasingam G; Rogak LJ; Reeve BB; Snyder C; Bruner D; Cella D; Kottschade LA; Perlmutter J; Geoghegan C; Samuel-Ryals CA; Given B; Mazza GL; Miller R; Strasser JF; Zylla DM; Weiss A; Blinder VS; Dueck AC
    JAMA; 2022 Jun; 327(24):2413-2422. PubMed ID: 35661856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-Sectional Patient-Reported Outcome Measuring of Health-Related Quality of Life With Establishment of Cancer- and Treatment-Specific Functional and Symptom Scales in Patients With Penile Cancer.
    Draeger DL; Sievert KD; Hakenberg OW
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1215-e1220. PubMed ID: 30201215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the patient experience of locally advanced or metastatic pancreatic cancer to inform patient-reported outcomes assessment.
    Herman JM; Kitchen H; Degboe A; Aldhouse NVJ; Trigg A; Hodgin M; Narang A; Johnson CD
    Qual Life Res; 2019 Nov; 28(11):2929-2939. PubMed ID: 31273624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.